🔎 Trials Near Me

Akèy › Myelom Miltip › Kentucky

Etid klinik pou Myelom Miltip nan Kentucky

15 etid pou Myelom Miltip ap chèche patisipan nan sit nan Kentucky.

Vil nan Kentucky

Tèks ofisyèl etid la (Anglè)

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  • Norton Cancer Institute, Louisville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Norton Cancer Institute, Louisville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04634552

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Norton Cancer Institute, Louisville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

  • Norton Healthcare, Inc., Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04879043

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Norton Women's and Children's Hospital, Louisville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
  • Commonwealth Cancer Center-Corbin, Corbin
  • Saint Joseph Radiation Oncology Resource Center, Lexington
  • ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, Louisville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  • Norton Cancer Institute St. Matthews, Louisville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Flaget Memorial Hospital, Bardstown
  • Commonwealth Cancer Center-Corbin, Corbin
  • Saint Joseph Hospital, Lexington
  • ak 4 plis
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

  • Norton Cancer Institute, Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT03761108

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist Corbin, Corbin
  • Baptist Hardin, Elizabethtown
  • Baptist Lexington, Lexington
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

  • University of Kentucky/ Markey Cancer Center, Lexington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT05722418

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.